Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Chemomab Therapeutics Ltd. American Depositary Share

CMMB

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Last trade $1.65
Day change +$0.025 (+1.54%)
Day range $1.62 – $1.69
Volume 133,921
Market cap $13M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$13.04M
Price / earnings
—
Price / book
0.47×
Price / sales
—
EV / sales
—
EV / EBITDA
0.24×

Profitability

Earnings per share
-$3.89
Return on assets
-89.38%
Return on equity
-111.95%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.83×
Quick ratio
4.83×
Cash ratio
2.97×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$23.9M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CMMB, quarterly periods
Line itemQ1 FY2023 Mar 31, 2023Q4 FY2022 Dec 31, 2022Q3 FY2022 Sep 30, 2022Q2 FY2022 Jun 30, 2022Q1 FY2022 Mar 31, 2022Q4 FY2021 Dec 31, 2021Q3 FY2021 Sep 30, 2021Q2 FY2021 Jun 30, 2021
Revenue————————
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit————————
Selling, general and administrative$2.16M$2.75M$2.89M$3.34M$2.58M$2.64M$1.4M$1.45M
Research and development$6.89M$5.9M$5.42M$2.91M$2.75M$2.38M$1.49M$1.31M
Total operating expenses$9.05M$8.64M$8.32M$6.25M$5.32M$5.02M$2.89M$2.75M
Operating income-$9.05M-$8.64M-$8.32M-$6.25M-$5.32M-$5.02M-$2.89M-$2.75M
Interest expense—$380K$237K-$480K—-$12K-$77K-$17K
Income before taxes-$8.73M-$8.26M-$8.08M-$6.73M-$5.1M-$5.04M-$2.97M-$2.77M
Income taxes$21K$10K$0-$544K$0$0$0$0
Net income-$8.75M-$8.27M-$8.08M-$6.19M-$5.1M-$5.04M-$2.97M-$2.77M
Net income attributable to common shareholders-$8.75M-$8.27M-$8.08M-$6.19M-$5.1M-$5.04M-$2.97M-$2.77M
EBITDA-$9.03M-$8.64M-$8.3M-$6.24M-$5.31M-$5.02M-$2.88M-$2.75M
Basic earnings per share-$0.16-$0.14-$0.14-$0.11-$0.09-$0.09-$0.05-$0.05
Diluted earnings per share-$0.16-$0.14-$0.14-$0.11-$0.09-$0.09-$0.05-$0.05

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

Chemomab Therapeutics reported Q1 2026 financial results showing a net loss of $1.8 million and cash position of $8.0 million (runway through Q1 2027). The company presented new clinical data at major medical conferences demonstrating nebokitug's disease-modifying potential in primary sclerosing cholangitis (PSC) and potential benefits for PSC patients with co-existing inflammatory bowel disease (IBD). Multiple proteomic and gene expression analyses showed dose-dependent reductions in fibrosis and inflammatory biomarkers. The company continues advancing strategic partnership discussions for nebokitug.

GlobeNewswire Inc.

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics reported positive 2025 results highlighted by successful FDA End-of-Phase 2 meeting for nebokitug in primary sclerosing cholangitis (PSC), establishing a clear pathway to potential regulatory approval based on a single Phase 3 trial. The company's Phase 2 SPRING trial data showed nebokitug was safe and well-tolerated with improvements in inflammation and fibrosis biomarkers. Cash position of $10.4 million is expected to fund operations through Q1 2027, with R&D expenses declining to $5.8 million for 2025 as the Phase 2 trial completed.

GlobeNewswire Inc.

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Chemomab's CM-101 demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic activity in a Phase 2 trial for primary sclerosing cholangitis, a rare liver disease. The data supports further clinical development of CM-101 for this condition.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 26, 20251-for-4reverse split